BioCorteX key facts
as of Oct 2026- Operator of a biotechnology company intended to deliver effective therapeutics and de-risk the pharma pipeline by leveraging the synergy between drugs and bacteria.
- BioCorteX is valued at approximately $13.3M as of Oct 2026 (last reported valuation).
- It has raised $5.2M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Draper Associates, Sofinnova Partners, Hoxton Ventures, Grow London, Merck Digital Sciences Studio — 7 tracked in total.
- Status: Privately Held (backing).
BioCorteX's last reported valuation, Mar 2023. Nothing priced has surfaced since.
- ·Watch BioCorteX: the Monday email on marks, rounds and moves
BioCorteX funding rounds
No funding rounds for BioCorteX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
BioCorteX valuation
BioCorteX's last reported valuation was $13.3 million in Mar 2023. No priced round, secondary trade or fund mark has surfaced since.
BioCorteX investors
7 investors are on record for BioCorteX, including Draper Associates, Sofinnova Partners, Hoxton Ventures and Grow London.
About BioCorteX
Operator of a biotechnology company intended to deliver effective therapeutics and de-risk the pharma pipeline by leveraging the synergy between drugs and bacteria. The company uses deep technology to simulate how the colossal number of microbiota interact with a drug, de-risking preclinical studies and clinical trials, enabling medications, cosmetics, personal care, manufacturing, and agriculture sectors to provide patients with better therapies and treatments.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 13
- Website
- biocortex.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.